GO:0034141 positive regulation of toll-like receptor 3 signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034141 describes any process that activates or increases the frequency, rate, or extent of toll-like receptor 3 (TLR3) signaling, a double-stranded RNA-sensing antiviral and immune-activating pathway.
• TLR3 signaling is positively regulated at multiple nodes, including ligand availability, receptor trafficking, adaptor recruitment, and downstream NF-kB and interferon regulatory factor activation [2,4].
• Positive regulation of TLR3 signaling can promote antitumor immunity, as shown in lung adenocarcinoma where TLR3 activation enhances immune responses through NF-kB signaling.
• Cancer cells can escape TLR3-mediated apoptosis by downregulating TLR3 or its positive regulators, as observed in hepatocellular carcinoma and mesothelioma [5,6].
• TLR3 and interferon-beta mRNA are increased in peripheral blood of ischemic stroke patients with good outcome, linking positive regulation of TLR3 signaling to neuroinflammatory responses.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect which genes causally regulate TLR3 signaling in disease contexts [1,5,6,7].
Description
Toll-like receptor 3 (TLR3) is a pattern recognition receptor that detects double-stranded RNA, a molecular signature of viral infection, and initiates signaling cascades that produce type I interferons and proinflammatory cytokines. The Gene Ontology term GO:0034141, positive regulation of toll-like receptor 3 signaling pathway, captures any process that activates or increases the frequency, rate, or extent of this signaling pathway. Because TLR3 signaling sits at the interface of antiviral defense, inflammation, and cancer immunosurveillance, understanding its positive regulators is a major research priority [2,3]. Positive regulation of TLR3 signaling is not a single molecular event but a collection of mechanisms that amplify ligand sensing, receptor activation, adaptor recruitment, and downstream transcription factor activity [2,4]. For example, viral stress-inducible genes can feed back to enhance TLR3-dependent interferon responses, creating a positive amplification loop. In cancer, TLR3 activation can unleash apoptosis or antitumor immunity, but tumors often downregulate TLR3 or its positive regulators to escape these effects [5,6,7]. This article integrates the QuickGO definition of GO:0034141 with verified PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease relevance, and experimental models used to study positive regulation of TLR3 signaling. Researchers can use this framework to design CRISPR-based studies that test causality of candidate regulators in immune, cancer, and neuroinflammatory contexts [1,5,6,7,8].
positive regulation of toll-like receptor 3 signaling pathway At A Glance
| GO ID | GO:0034141 |
|---|---|
| GO term | positive regulation of toll-like receptor 3 signaling pathway |
| Ontology | biological_process |
| Synonym | positive regulation of TLR3 signaling pathway; positive regulation of toll-like receptor 3 signalling pathway |
| Major function | Amplification of dsRNA-triggered TLR3 signaling leading to enhanced type I interferon and proinflammatory cytokine responses [2,3] |
| Upstream input | Double-stranded RNA, viral infection, and stress-inducible genes that increase TLR3 ligand availability or receptor activity [2,3] |
| Key adaptor | TRIF (TICAM1) is the central adaptor for TLR3 signaling and a target of positive regulation [2,4] |
| Downstream effectors | NF-kB, IRF3, and IRF7 transcription factors that drive interferon-beta and cytokine gene expression [2,7] |
| Disease relevance | Cancer immunosurveillance, apoptosis escape, and ischemic stroke outcome [5,6,7,8] |
What Is GO:0034141?
GO:0034141, positive regulation of toll-like receptor 3 signaling pathway, is defined by QuickGO as any process that activates or increases the frequency, rate, or extent of toll-like receptor 3 signaling pathway. In practical terms, this includes molecular events that enhance dsRNA sensing by TLR3, promote TLR3 dimerization or trafficking, strengthen recruitment of the adaptor TRIF, or amplify downstream signaling through NF-kB, IRF3, and IRF7, ultimately increasing interferon and cytokine production [2,4].
Why Is positive regulation of toll-like receptor 3 signaling pathway Important in Cell Biology?
Positive regulation of TLR3 signaling is critically important because it determines the strength and duration of innate immune responses to viral dsRNA and shapes outcomes in cancer, autoimmunity, and neuroinflammation [2,3]. Enhancing TLR3 signaling can promote antitumor immunity in lung adenocarcinoma through NF-kB signaling, while loss of TLR3 or its positive regulators allows tumors such as hepatocellular carcinoma and mesothelioma to escape apoptosis [5,6,7]. In ischemic stroke, increased TLR3 and interferon-beta mRNA in peripheral blood is associated with good outcome, suggesting that positive regulation of this pathway may be protective in some neurological contexts. Thus, identifying the genes and mechanisms that positively regulate TLR3 signaling is essential for understanding disease pathogenesis and for developing targeted immunotherapies.
• TLR3 signaling is a first-line antiviral defense that detects dsRNA and induces type I interferons [2,3].
• Positive regulation of TLR3 signaling amplifies interferon and cytokine production, shaping innate and adaptive immunity [2,4].
• TLR3 activation enhances antitumor immune responses in lung adenocarcinoma through NF-kB signaling.
• Downregulation of TLR3 or its positive regulators is an escape mechanism from apoptosis during hepatocarcinogenesis.
• Cisplatin can unleash TLR3-mediated apoptosis by downregulating c-FLIP in malignant mesothelioma, linking positive regulation to chemotherapy response.
• TLR3 and interferon-beta mRNA are increased in ischemic stroke patients with good outcome, implicating positive regulation in neuroprotection.
• Viral stress-inducible genes can feed back to enhance TLR3 signaling, creating positive amplification loops.
• Modulation of Toll-interleukin 1 receptor signaling reveals conserved regulatory mechanisms that can be targeted experimentally.
• CRISPR screens and knockout models are needed to identify causal positive regulators of TLR3 signaling in disease contexts [1,5,6,7].
• Understanding positive regulation of TLR3 signaling can guide development of TLR3 agonists or inhibitors for immunotherapy.
What Happens During positive regulation of toll-like receptor 3 signaling pathway?
Ligand availability and dsRNA sensing
In simple terms: More dsRNA or better access to dsRNA makes TLR3 signaling stronger.
TLR3 is activated by double-stranded RNA, a common viral replication intermediate. Positive regulation can occur when viral stress-inducible genes increase the availability of dsRNA or enhance its delivery to endosomal TLR3. For example, viral stress-inducible genes are known to amplify antiviral responses, indirectly increasing TLR3 signaling capacity. In cancer, TLR3 activation by synthetic dsRNA analogs can enhance antitumor immune responses, demonstrating that ligand availability is a rate-limiting step for positive regulation.
Receptor trafficking and dimerization
In simple terms: Getting TLR3 to the right place and helping it pair up boosts signaling.
TLR3 must traffic to endosomes and dimerize to initiate signaling. Positive regulation of TLR3 signaling includes processes that promote receptor trafficking, stabilization, or dimerization. Modulation of Toll-interleukin 1 receptor mediated signaling highlights that receptor-proximal events are tightly regulated and can be enhanced or suppressed. In hepatocellular carcinoma, TLR3 downregulation is an escape mechanism, implying that positive regulators of TLR3 trafficking or stability are required for effective signaling.
Adaptor recruitment and signalosome assembly
In simple terms: TRIF and other adaptors assemble a signaling platform that amplifies the response.
Upon dsRNA binding, TLR3 recruits the adaptor TRIF (TICAM1), which nucleates a signalosome that activates NF-kB and IRF3/IRF7 [2,4]. Positive regulation of TLR3 signaling can occur through enhanced TRIF recruitment or stabilization of the signalosome. Toll-like receptor family and signalling pathway reviews describe how adaptor usage determines downstream output. Modulation of Toll-interleukin 1 receptor mediated signaling further shows that adaptor-level regulation is a conserved control point.
NF-kB and IRF activation
In simple terms: The signal reaches the nucleus and turns on interferon and cytokine genes.
Downstream of TRIF, NF-kB and IRF3/IRF7 translocate to the nucleus and induce interferon-beta and proinflammatory cytokines [2,7]. Positive regulation of TLR3 signaling increases the frequency, rate, or extent of these transcriptional events. In lung adenocarcinoma, TLR3 activation enhances antitumor immune response through NF-kB signaling, directly linking positive regulation to NF-kB output. Viral stress-inducible genes can further amplify interferon responses, creating a positive feedback loop.
Apoptosis and immune amplification
In simple terms: Strong TLR3 signaling can kill tumor cells or call in immune cells.
Positive regulation of TLR3 signaling can trigger apoptosis in malignant cells. Cisplatin unleashes TLR3-mediated apoptosis through downregulation of c-FLIP in malignant mesothelioma, showing that positive regulation can be pharmacologically enhanced. Conversely, TLR3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis, indicating that loss of positive regulation promotes tumor survival. In ischemic stroke, increased TLR3 and interferon-beta mRNA in peripheral blood of patients with good outcome suggests that positive regulation may also shape neuroinflammatory recovery.
Key Genes Involved in GO:0034141 positive regulation of toll-like receptor 3 signaling pathway
The following genes and proteins are central to positive regulation of TLR3 signaling, based on verified literature and their established roles in the pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TLR3 | dsRNA sensor and initiator of the pathway | Knockout or knockdown validates pathway dependence; downregulation is an escape mechanism in hepatocarcinogenesis |
| TICAM1 (TRIF) | Central adaptor for TLR3 signaling | Essential for signalosome assembly; target for positive regulation studies [2,4] |
| NFKB1 | Transcription factor downstream of TLR3 | Mediates antitumor immune response in lung adenocarcinoma |
| IRF3 | Transcription factor inducing interferon-beta | Readout of positive regulation; activated downstream of TRIF |
| IRF7 | Amplifier of type I interferon production | Positive regulation enhances IRF7-driven interferon loops |
| IFNB1 | Interferon-beta cytokine | Increased in ischemic stroke patients with good outcome; marker of TLR3 pathway activity |
| CXCL10 | Chemokine downstream of TLR3/NF-kB | Links TLR3 signaling to immune cell recruitment; modulated by FGFR4 in colon cancer |
| CXCR3 | Receptor for CXCL10 | Mediates immune cell migration in tumor microenvironment |
| FGFR4 | Receptor tyrosine kinase promoting CAF activation | Regulates CXCL10-CXCR3 axis; potential modifier of TLR3-related inflammation |
| CFLAR (c-FLIP) | Apoptosis inhibitor | Downregulation by cisplatin unleashes TLR3-mediated apoptosis in mesothelioma |
| IL1R1 | Toll-interleukin 1 receptor family member | Shares regulatory mechanisms with TLR3 signaling |
| MYD88 | Adaptor for other TLRs | Contrasts with TRIF-dependent TLR3 signaling; useful for specificity controls |
| TRAF3 | E3 ubiquitin ligase in TLR3 pathway | Modulates IRF3 activation; potential positive regulator |
| TRAF6 | E3 ubiquitin ligase in TLR3 pathway | Modulates NF-kB activation; potential positive regulator |
| TBK1 | Kinase activating IRF3 | Phosphorylates IRF3 downstream of TRIF; positive regulator node |
| IKBKE | Kinase activating IRF3 | Cooperates with TBK1; positive regulator node |
| STAT1 | Transcription factor for interferon responses | Amplifies interferon-stimulated genes downstream of TLR3 |
| ISG15 | Interferon-stimulated gene | Viral stress-inducible gene that can amplify antiviral responses |
How Is positive regulation of toll-like receptor 3 signaling pathway Regulated?
Positive regulation of TLR3 signaling is controlled at multiple levels. Viral stress-inducible genes can enhance interferon responses, creating positive feedback loops that amplify TLR3 signaling. Modulation of Toll-interleukin 1 receptor mediated signaling reveals conserved regulatory mechanisms that can either promote or suppress pathway activity. In cancer, FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis, indirectly shaping the inflammatory microenvironment that influences TLR3 signaling. Additionally, cisplatin can downregulate c-FLIP to unleash TLR3-mediated apoptosis, demonstrating pharmacological regulation of the pathway. These examples show that positive regulation is dynamic and context-dependent, requiring experimental dissection in each disease model.
positive regulation of toll-like receptor 3 signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TLR3 | Hepatocellular carcinoma apoptosis escape | TLR3 knockout or knockdown in hepatoma cell lines; overexpression to restore apoptosis |
| CFLAR (c-FLIP) | Malignant mesothelioma apoptosis | Point mutation or knockout of CFLAR to sensitize cells to TLR3-mediated apoptosis |
| NFKB1 | Lung adenocarcinoma antitumor immunity | NFKB1 knockout or overexpression in lung cancer cells; TLR3 agonist treatment |
| IFNB1 | Ischemic stroke outcome | IFNB1 reporter knock-in in neuronal or immune cells; TLR3 stimulation |
| FGFR4 | Colon cancer CAF activation | FGFR4 knockout or point mutation in cancer-associated fibroblasts; CXCL10-CXCR3 axis readout |
Cancer immunosurveillance and apoptosis escape
Positive regulation of TLR3 signaling can enhance antitumor immune responses in lung adenocarcinoma through NF-kB signaling. However, tumors can escape TLR3-mediated apoptosis by downregulating TLR3, as shown in hepatocarcinogenesis. In malignant mesothelioma, cisplatin unleashes TLR3-mediated apoptosis through downregulation of c-FLIP, suggesting that positive regulation can be pharmacologically restored. These findings position TLR3 positive regulators as potential therapeutic targets or biomarkers in oncology.
Ischemic stroke and neuroinflammation
TLR3 and interferon-beta mRNA expressions were increased in peripheral blood of ischemic stroke patients with good outcome, indicating that positive regulation of TLR3 signaling may be associated with favorable neurological recovery. This links the pathway to neuroinflammatory responses and suggests that modulating TLR3 activity could influence stroke outcomes.
Viral infection and interferon amplification
Viral stress-inducible genes are part of the host antiviral response and can amplify TLR3 signaling by increasing interferon production. This positive feedback loop is critical for controlling viral replication but may also contribute to immunopathology if dysregulated. Understanding these mechanisms is essential for antiviral therapy design.
Tumor microenvironment and chemokine networks
FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer, illustrating how chemokine networks intersect with TLR3-related inflammatory signaling. Positive regulation of TLR3 signaling may influence CXCL10 production and immune cell recruitment, shaping the tumor microenvironment.
From positive regulation of toll-like receptor 3 signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is TLR3 required for dsRNA-induced interferon responses? | TLR3 knockout cell line or primary cells [2,6] |
| Does a candidate gene positively regulate TLR3 signaling? | CRISPR knockout and overexpression of the candidate gene followed by TLR3 agonist stimulation [4,7] |
| Does a point mutation in TRIF affect signalosome assembly? | Point-mutation knock-in of TICAM1 in a TLR3-expressing cell line [2,4] |
| Can restoring TLR3 expression reverse apoptosis escape? | Knock-in or overexpression of TLR3 in TLR3-downregulated tumor cells |
| Does c-FLIP downregulation enhance TLR3-mediated apoptosis? | CFLAR knockout or point mutation in mesothelioma cells treated with cisplatin |
| Is NF-kB activation required for TLR3-driven antitumor immunity? | NFKB1 knockout in lung adenocarcinoma cells with TLR3 agonist treatment |
How to Study the positive regulation of toll-like receptor 3 signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptional changes | Identify interferon-stimulated genes and cytokines induced by TLR3 activation [3,7] |
| qPCR | Expression of specific genes | Quantify IFNB1, CXCL10, and ISGs after TLR3 stimulation |
| Co-immunoprecipitation | Protein-protein interactions | Detect TRIF signalosome assembly and adaptor recruitment [2,4] |
| Western blot | Protein phosphorylation and abundance | Measure IRF3 phosphorylation, NF-kB activation, and c-FLIP levels [5,7] |
| Flow cytometry | Apoptosis and immune cell activation | Assess TLR3-mediated apoptosis and immune cell recruitment [5,6] |
| CRISPR knockout screen | Gene requirement for pathway activity | Identify novel positive regulators of TLR3 signaling [1,4] |
| Luciferase reporter assay | Transcription factor activity | Measure NF-kB or IRF3-driven promoter activity after TLR3 stimulation |
| ELISA | Cytokine secretion | Quantify interferon-beta and CXCL10 in culture supernatants [3,8] |
Transcriptional profiling of TLR3 pathway activation
RNA-seq or qPCR can measure interferon-beta, CXCL10, and other downstream genes after TLR3 stimulation to quantify positive regulation [3,7,8]. Comparing wild-type and knockout cells identifies genes required for pathway activity.
Protein-level analysis of signalosome assembly
Co-immunoprecipitation and western blotting can assess TRIF recruitment, TBK1/IKBKE activation, and IRF3 phosphorylation following TLR3 stimulation [2,4]. These methods reveal whether a candidate regulator acts at the adaptor or kinase level.
Apoptosis and viability assays
Flow cytometry and caspase activity assays can measure TLR3-mediated apoptosis in cancer cells, as demonstrated in mesothelioma and hepatocellular carcinoma models [5,6]. These assays link positive regulation to functional outcomes.
CRISPR screens for positive regulators
Genome-wide CRISPR knockout or activation screens coupled with TLR3 agonist treatment and interferon reporter readouts can identify novel positive regulators of TLR3 signaling [1,4]. Hits can be validated individually with knockout and overexpression models.
How CRISPR Can Be Used to Study GO:0034141 positive regulation of toll-like receptor 3 signaling pathway
Knockout
CRISPR knockout of TLR3, TICAM1, or candidate positive regulators can abolish or reduce TLR3 signaling, providing causal evidence for their role [2,4,6]. For example, TLR3 knockout in hepatoma cells can test whether TLR3 downregulation mediates apoptosis escape.
Point Mutation
Point mutations can dissect specific residues required for positive regulation, such as phosphorylation sites in IRF3 or ubiquitination sites in TRAF3 [2,4]. Knock-in of point mutants allows precise structure-function analysis without confounding expression changes.
Knock-in
Knock-in of reporter genes (e.g., IFNB1-luciferase) or tagged alleles (e.g., TRIF-HA) enables real-time monitoring of TLR3 pathway activation and signalosome dynamics [2,3]. This is useful for screening positive regulators in live cells.
Overexpression
CRISPR activation or cDNA overexpression of candidate genes can test whether increasing their levels enhances TLR3 signaling [4,7]. Overexpression of TLR3 itself can restore dsRNA responsiveness in cells that have downregulated the receptor.
How EDITGENE Supports positive regulation of toll-like receptor 3 signaling pathway Research
Researchers studying positive regulation of toll-like receptor 3 signaling pathway-related genes often need to determine whether a candidate gene is causally involved in enhancing or dampening the pathway. EDITGENE provides CRISPR-based cell model services that enable precise genetic manipulation to answer these questions.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of toll-like receptor 3 signaling pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| F2RL1 Knockout HEK293T Cell Line | EDJ-KQ222 | Human | 2150 | Details Get a Quote |
| TIRAP Knockout HEK293 Cell Line | EDJ-KQ594 | Human | 114609 | Details Get a Quote |
| PTPN22 Knockout HEK293 Cell Line | EDJ-KQ3809 | Human | 26191 | Details Get a Quote |
| TRIM3 Knockout HEK293 Cell Line | EDJ-KQ7108 | Human | 10612 | Details Get a Quote |
| WDFY1 Knockout HEK293 Cell Line | EDJ-KQ15347 | Human | 57590 | Details Get a Quote |
| F2RL1 Knockout HEK293 Cell Line | EDJ-KQ17871 | Human | 2150 | Details Get a Quote |
| TIRAP Knockout A-549 Cell Line | EDJ-KQ19032 | Human | 114609 | Details Get a Quote |
| TIRAP Knockout HCT 116 Cell Line | EDJ-KQ19033 | Human | 114609 | Details Get a Quote |
| TIRAP Knockout HeLa Cell Line | EDJ-KQ19034 | Human | 114609 | Details Get a Quote |
| F2RL1 Knockout HCT 116 Cell Line | EDJ-KQ25963 | Human | 2150 | Details Get a Quote |
| TRIM3 Knockout A-549 Cell Line | EDJ-KQ31968 | Human | 10612 | Details Get a Quote |
| TRIM3 Knockout HCT 116 Cell Line | EDJ-KQ31969 | Human | 10612 | Details Get a Quote |
| F2RL1 Knockout A-549 Cell Line | EDJ-KQ27222 | Human | 2150 | Details Get a Quote |
| F2RL1 Knockout HeLa Cell Line | EDJ-KQ27223 | Human | 2150 | Details Get a Quote |
| TRIM3 Knockout HeLa Cell Line | EDJ-KQ30591 | Human | 10612 | Details Get a Quote |
Displaying Records 1 To 15 Of 22 Records
Frequently Asked Questions About positive regulation of toll-like receptor 3 signaling pathway
What is GO:0034141?
GO:0034141 is the Gene Ontology term for positive regulation of toll-like receptor 3 signaling pathway, defined as any process that activates or increases the frequency, rate, or extent of TLR3 signaling.
What genes are involved in positive regulation of TLR3 signaling?
Key genes include TLR3, TICAM1 (TRIF), NFKB1, IRF3, IRF7, IFNB1, CXCL10, and CFLAR, among others [2,4,5,7].
How does TLR3 signaling get activated?
TLR3 is activated by double-stranded RNA, which triggers receptor dimerization, TRIF recruitment, and downstream NF-kB and IRF activation [2,3].
Why is positive regulation of TLR3 signaling important in cancer?
It can enhance antitumor immunity in lung adenocarcinoma and trigger apoptosis in mesothelioma, but tumors can escape by downregulating TLR3 [5,6,7].
What diseases are linked to TLR3 signaling?
Cancer, ischemic stroke, and viral infections are linked to TLR3 signaling and its positive regulation [3,5,6,7,8].
How can I study positive regulators of TLR3 signaling?
CRISPR knockout, point mutation, knock-in reporters, and overexpression models combined with RNA-seq, western blot, and apoptosis assays are standard approaches [1,4,5,7].
What is the role of TRIF in TLR3 signaling?
TRIF (TICAM1) is the central adaptor that links TLR3 activation to downstream NF-kB and IRF3 activation [2,4].
Can TLR3 signaling be targeted therapeutically?
TLR3 agonists are being explored for cancer immunotherapy, and modulating positive regulators may enhance or restore pathway activity [5,7].
What is the relationship between TLR3 and interferon-beta?
TLR3 activation induces interferon-beta, which amplifies antiviral and immune responses; IFNB1 mRNA is a readout of pathway activity [3,8].
How does cisplatin affect TLR3-mediated apoptosis?
Cisplatin downregulates c-FLIP, unleashing TLR3-mediated apoptosis in malignant mesothelioma.
Conclusion
GO:0034141, positive regulation of toll-like receptor 3 signaling pathway, is a critical biological process that amplifies dsRNA-triggered innate immune responses. Its positive regulators influence antiviral defense, cancer immunosurveillance, apoptosis, and neuroinflammation, as demonstrated in lung adenocarcinoma, hepatocellular carcinoma, mesothelioma, and ischemic stroke [5,6,7,8]. Understanding these mechanisms requires precise genetic models, and CRISPR-based knockout, point-mutation, knock-in, and overexpression approaches are indispensable for causal dissection [1,4,5,7]. Future research should focus on identifying novel positive regulators and translating these findings into immunotherapeutic strategies.
References
- 1. Sun EG et al.. 2025. FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer.. Cell Death Dis 16(1):424 PMID: 40447617
- 2. Muzio M et al.. 2000. Toll-like receptor family and signalling pathway.. Biochem Soc Trans 28(5):563-6 PMID: 11044375
- 3. Sen GC et al.. 2007. Viral stress-inducible genes.. Adv Virus Res 70:233-63 PMID: 17765707
- 4. Li X et al.. 2005. Modulation of Toll-interleukin 1 receptor mediated signaling.. J Mol Med (Berl) 83(4):258-66 PMID: 15662540
- 5. Vanbervliet-Defrance B et al.. 2020. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.. Cancer Lett 472:29-39 PMID: 31838086
- 6. Bonnin M et al.. 2019. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.. J Hepatol 71(4):763-772 PMID: 31220470
- 7. Li A et al.. 2025. Toll-like receptor 3 activation enhances antitumor immune response in lung adenocarcinoma through NF-κB signaling pathway.. Front Immunol 16:1585747 PMID: 40406122
- 8. Deng L et al.. 2017. Toll-Like Receptor 3 and Interferon β mRNA Expressions Were Increased in Peripheral Blood of Ischemic Stroke Patients with Good Outcome.. J Stroke Cerebrovasc Dis 26(3):559-566 PMID: 28017496
